348 related articles for article (PubMed ID: 26334961)
21. Gelatin nanocarriers as potential vectors for effective management of tuberculosis.
Saraogi GK; Gupta P; Gupta UD; Jain NK; Agrawal GP
Int J Pharm; 2010 Jan; 385(1-2):143-9. PubMed ID: 19819315
[TBL] [Abstract][Full Text] [Related]
22. Particulate pulmonary delivery systems containing anti-tuberculosis agents.
Gupta A; Pandya SM; Mohammad I; Agrawal AK; Mohan M; Misra A
Crit Rev Ther Drug Carrier Syst; 2013; 30(4):277-91. PubMed ID: 23662603
[TBL] [Abstract][Full Text] [Related]
23. Zinc-alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying.
Möbus K; Siepmann J; Bodmeier R
Eur J Pharm Biopharm; 2012 May; 81(1):121-30. PubMed ID: 22342605
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid.
Pourshahab PS; Gilani K; Moazeni E; Eslahi H; Fazeli MR; Jamalifar H
J Microencapsul; 2011; 28(7):605-13. PubMed ID: 21793647
[TBL] [Abstract][Full Text] [Related]
25. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
[TBL] [Abstract][Full Text] [Related]
26. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis.
Parikh R; Dalwadi S; Aboti P; Patel L
J Antibiot (Tokyo); 2014 May; 67(5):387-94. PubMed ID: 24569669
[TBL] [Abstract][Full Text] [Related]
27. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
28. Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers.
Choonara YE; Pillay V; Ndesendo VM; du Toit LC; Kumar P; Khan RA; Murphy CS; Jarvis DL
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):243-54. PubMed ID: 21664111
[TBL] [Abstract][Full Text] [Related]
29. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.
Sharma R; Saxena D; Dwivedi AK; Misra A
Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2006 May; 27(5):409-16. PubMed ID: 16624533
[TBL] [Abstract][Full Text] [Related]
31. Porous particles and novel carrier particles with enhanced penetration for efficient pulmonary delivery of antitubercular drugs.
Tse JY; Koike A; Kadota K; Uchiyama H; Fujimori K; Tozuka Y
Eur J Pharm Biopharm; 2021 Oct; 167():116-126. PubMed ID: 34363979
[TBL] [Abstract][Full Text] [Related]
32. Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation,
Shrivastava P; Gautam L; Sharma R; Dube D; Vyas S; Vyas SP
J Microencapsul; 2021 Mar; 38(2):108-123. PubMed ID: 33267623
[TBL] [Abstract][Full Text] [Related]
33. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
34. Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies.
Viswanathan V; Pharande R; Bannalikar A; Gupta P; Gupta U; Mukne A
Drug Dev Ind Pharm; 2019 Jan; 45(1):11-20. PubMed ID: 30122088
[TBL] [Abstract][Full Text] [Related]
35. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
[TBL] [Abstract][Full Text] [Related]
36. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis.
Saraogi GK; Sharma B; Joshi B; Gupta P; Gupta UD; Jain NK; Agrawal GP
J Drug Target; 2011 Apr; 19(3):219-27. PubMed ID: 20540651
[TBL] [Abstract][Full Text] [Related]
37. Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs.
Mehta SK; Jindal N
Colloids Surf B Biointerfaces; 2013 Jan; 101():434-41. PubMed ID: 23010052
[TBL] [Abstract][Full Text] [Related]
38. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization.
Parumasivam T; Leung SS; Quan DH; Triccas JA; Britton WJ; Chan HK
Eur J Pharm Sci; 2016 Jun; 88():1-11. PubMed ID: 27049049
[TBL] [Abstract][Full Text] [Related]
39. Formulation and optimization of alkaline extracted ispaghula husk microparticles of isoniazid - in vitro and in vivo assessment.
Maurya DP; Sultana Y; Aqil M; Kumar D; Chuttani K; Ali A; Mishra AK
J Microencapsul; 2011; 28(6):472-82. PubMed ID: 21561399
[TBL] [Abstract][Full Text] [Related]
40. Anti-tuberculosis drug combination for controlled oral delivery using 3D printed compartmental dosage forms: From drug product design to in vivo testing.
Genina N; Boetker JP; Colombo S; Harmankaya N; Rantanen J; Bohr A
J Control Release; 2017 Dec; 268():40-48. PubMed ID: 28993169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
